RNXT
RenovoRx, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Shaun R. Bagai
IPO Date
2021-08-26
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
RenovoRx, Inc.
CEO
Shaun R. Bagai
IPO Date
2021-08-26
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 946,107 |
| $0.98 |
| 7 Apr 2026 | VOLL MARK | Chief Financial Officer | A-Award | Acquired | 80,000 | $0.00 |
| 7 Apr 2026 | Gentry Leesa | Chief Clinical Officer | A-Award | Acquired | 128,550 | $0.98 |
| 7 Apr 2026 | Agah Ramtin | director, officer: Chief Medical Officer | A-Award | Acquired | 621,727 | $0.98 |
| 27 Mar 2026 | VOLL MARK | Chief Financial Officer | A-Award | Acquired | 12,380 | $0.00 |
| 24 Mar 2026 | Marton Laurence | director | P-Purchase | Acquired | 9,720 | $0.00 |
| 24 Mar 2026 | Marton Laurence | director | P-Purchase | Acquired | 4,860 | $1.93 |
| 24 Mar 2026 | Bagai Shaun | director, officer: Chief Executive Officer | P-Purchase | Acquired | 24,300 | $0.00 |
| 24 Mar 2026 | Bagai Shaun | director, officer: Chief Executive Officer | P-Purchase | Acquired | 12,150 | $1.93 |